Leading Botanical Science and Health Advocacy Groups Applaud Federal Action to Ban Synthetic 7-OH and Clear Path for Kratom Reform
The announcement, on the morning of July 29, 2025, was delivered by HHS Secretary Robert F. Kennedy, Jr. and FDA Commissioner Dr. Marty Makary, signaling a coordinated federal response to the widespread sale of mislabeled and chemically altered products masquerading as kratom that pose significant health risks.
'This is a long-overdue correction,' said Dr. Paloma Lehfeldt, medical advisor to Botanicals for Better Health and Wellness (BBHW). 'By clearly separating the natural botanical kratom from synthetic compounds like 7-hydroxymitragynine, which have been misleadingly marketed under the same name, federal agencies are addressing a major source of consumer confusion. These actions will protect consumers while preserving access to a culturally significant botanical with potential therapeutic value, while moving toward a more rational, evidence-informed regulatory approach.'
SABER, a coalition of scientists and educators advancing evidence-based botanical research, applauded the bifurcation of the botanical kratom from synthetic drugs like 7-OH. 7-hydroxymitragynine, a synthetic drug manufactured using industrial oxidizers, exhibits high opioid receptor affinity and has been linked to respiratory depression and toxicity. It is not found in natural kratom leaves at physiologically relevant levels. By contrast, kratom's primary alkaloid, mitragynine, is a partial receptor agonist with low abuse potential, and recent FDA-funded studies have confirmed its favorable safety profile at doses up to 140 mg in healthy adults.
'For too long, the conversation around kratom has been polluted by bad actors and misinformation,' said Dr. Paula Brown, a member of the SABER steering committee and director of natural health and food products research at the British Columbia Institute of Technology (BCIT). 'FDA's data now supports what scientists have known for years: kratom is not a narcotic, and 7-OH is not a natural constituent of the plant. Differentiating them is both scientifically necessary and ethically urgent.'
BBHW and SABER are calling on FDA to finalize the following actions:
'This is what responsible botanical regulation looks like,' said Dr. Mary Hardy, MD, SABER steering committee member and integrative medicine researcher. 'Science, not stigma, must guide public health policy.'
About Scientific Association for Botanical Education and Research (SABER)
The Scientific Association for Botanical Education and Research (SABER) is a nonprofit organization dedicated to advancing scientific understanding, regulation, and safe access to botanicals. Through research partnerships, policy advocacy, and public education, SABER works to ensure that natural products are studied responsibly, used safely, and regulated appropriately. To learn more, visit www.saberscience.org.
Media Contact
Paloma Lehfeldtinfo@saberscience.org
###
SOURCE: Scientific Association for Botanical Education and Research (SABER)
Copyright 2025 EZ Newswire
See release on EZ Newswire
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
7 hours ago
- The Independent
Undeclared milk leads to US-wide butter recall
A voluntary recall has been issued for over 64,000 pounds of Bunge North America's NH European Style Butter Blend due to undeclared milk, a common allergen. The recall was initiated on 14 July and classified as a Class II recall by the FDA. The affected butter was distributed to 12 US centres and one in the Dominican Republic. This butter recall is part of a series of recent food and drink issues, including High Noon Vodka Seltzer being recalled as it was mislabeled as non-alcoholic energy drinks. Consumers are advised to check affected products and dispose of or return them.
Medical News Today
2 days ago
- Medical News Today
Does Ozempic make you lose muscle?
Ozempic can cause muscle loss along with weight loss. Studies have shown that some people using Ozempic can lose both fat and muscle. If you're concerned with muscle loss while using Ozempic, be sure to talk with your (semaglutide) belongs to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 agonists). Ozempic is approved by the Food and Drug Administration (FDA) for use in people with type 2 diabetes with certain can cause a loss of appetite, which can cause you to lose weight. This includes fat loss, muscle loss, and possibly bone density. Keep reading to learn strategies to help preserve muscle and maintain bone health while using Ozempic is not approved by the FDA for weight loss or weight management. However, some doctors may prescribe the drug off-label for this use. With off-label use, doctors prescribe a drug for a use other than an FDA-approved use. The drug Wegovy contains the same active ingredient as Ozempic, semaglutide, but it comes in higher strengths, and it's approved for weight loss or weight management in certain effects of rapid weight lossThere are concerns about Ozempic's effects on muscle mass and strength. Clinical trials have not specifically linked Ozempic to direct muscle loss. However, some individuals may have a lower appetite, leading to weight loss, which can include loss of both fat and one clinical trial, 86.4% of people taking semaglutide lost 5% or more of their body weight, while 69.1% of people taking the drug lost 10% or have shown that GLP-1 drugs can reduce lean mass, but the results are mixed. (Lean mass can refer to muscle mass, organ size, bone mass, fluids, and water in fat tissue.) For example, semaglutide has been linked to a 40% reduction in lean mass, while liraglutide has been linked to a reduction of up to 60%. (Liraglutide is the active ingredient in the GLP-1 drug Victoza.) Another study comparing semaglutide and tirzepatide with placebo (a drug with no active ingredient) showed a 15% or less decrease in lean mass across all groups. (Tirzepatide is the active ingredient in the GLP-1 drug Zepbound.)Rapid weight loss associated with GLP-1 medications may also affect bone density. A small study showed that people using Victoza had lower bone mineral density in the hip and spine compared to people taking a placebo. However, more studies, especially in different populations, are needed to fully understand the long-term effects of GLP-1 medications on bone weight loss can be beneficial and improve overall health, losing weight rapidly may weaken your musculoskeletal system and cause other health concerns. If you're taking GLP-1 drugs, such as Ozempic, it's important to talk with your doctor about ways to maintain or increase your muscle mass, especially if you experience significant weight muscle loss with OzempicBelow are some strategies that may help prevent muscle loss while using Ozempic:Increase your protein intake: Consuming more protein in your meals can help maintain muscle mass while using Ozempic. This is especially important for older adults and those with other conditions in addition to type 2 diabetes. Diets high in protein can help prevent the loss of lean mass while increasing fat loss. Your doctor or a dietitian can help you determine whether you're getting enough protein in your on strength training: Exercise, especially resistance training, can effectively preserve muscle mass and increase muscle strength and bone density during treatment with GLP-1 drugs. Your doctor can help you determine the right strength training exercises for you. They may also refer you to an exercise therapist if your body composition: To know whether you're maintaining muscle mass with Ozempic, it's important to monitor your body composition with your doctor or another healthcare professional. Body composition measurements can tell you what percentage of fat and muscle you have. Regular assessments can help you and your doctor adjust your diet or exercise plan as needed. Note: Before making changes to your diet or exercise plan, it's important to talk with your doctor to make sure these changes are right for treatments that may help prevent muscle lossA 2025 clinical trial has shown that taking bimagrumab and semaglutide together enhances fat loss and preserves muscle in adults with overweight or obesity. Bimagrumab is a monoclonal antibody drug that has been studied for its effect on promoting fat loss and increasing muscle mass in certain adults with obesity and type 2 is not yet approved for use by the FDA, and it's not approved for use with semaglutide as a combination therapy. But initial research shows the potential of new treatments to help preserve muscle mass in people taking GLP-1 medications like Ozempic is effective for weight loss, it is important to be aware of its potential side effects on muscle and bone health. Strategies such as increasing protein intake, focusing on strength training exercises, and monitoring body composition can help prevent muscle loss while using Ozempic. If you have concerns about losing muscle during Ozempic treatment, be sure to talk with your Medical News Today has made every effort to make certain that all information is factually correct, comprehensive, and up to date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional. You should always consult your doctor or another healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Reuters
2 days ago
- Reuters
US FDA declines to approve Regeneron's blood cancer therapy for second time
Aug 1 (Reuters) - Regeneron (REGN.O), opens new tab said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, this time in relation to observations from the regulator's inspection at a third-party manufacturing site. The company was seeking approval for its drug odronextamab to treat follicular lymphoma — a type of cancer that begins in the lymph system, a part of the immune system — in patients whose cancer has returned and who have received at least two prior lines of treatment. The regulator had first declined to approve the therapy in March last year, seeking more data from enrollments in dose-finding and confirmatory portions of trials testing it. Regeneron said on Friday the latest FDA decision was due to its inspection at contract manufacturer Catalent's Indiana site, which was acquired by Danish drugmaker Novo Nordisk ( opens new tab. Catalent's Bloomington, Indiana facility is a fill-finish site for Regeneron's Eylea HD and odronextamab, and handles the final stages of drug preparation and packaging. The observations at the inspection have also resulted in delays to three applications for the high-dose version of its eye disease drug Eylea, Regeneron said, adding that Novo has been in communication with the FDA and expects to submit its response next week. There is clear frustration and exhaustion with the repeated regulatory setbacks, said Cantor analyst Carter Gould. Regeneron said the inspection was completed in mid-July and it anticipates an expeditious resolution of the issues. Odronextamab belongs to a class of treatments called bispecific antibodies, which are designed to attach to a cancer cell and an immune cell bringing them together so that the body's immune system can kill the cancer. The drug was approved by the European Commission in August 2024 to treat follicular lymphoma, and is branded as Ordspono in the region.
